2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1444

Validation of a Revised Version of the Michigan Body Map
Abstract Number: 379

Validation of a Short Calcium Intake List to Estimate Daily Dietary Calcium Intake of Patients with Osteoporosis
Abstract Number: 2393

Validation of a Web-Based Overlay for Sectoral Scoring of Active Lesions on MRI in Hip Osteoarthritis: Femoral Bone Marrow Lesions Predict Response to Intra-Articular Hyaluronate
Abstract Number: 95

Validation of Differential Methylation in Paternally Versus Maternally Transmitted Psoriatic Disease
Abstract Number: 787

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus
Abstract Number: 1916

Validation of Novel Biomarker Candidates for Systemic Sclerosis
Abstract Number: 3151

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Modules for Use in Childhood-Onset Lupus
Abstract Number: 2662

Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity
Abstract Number: 284

Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment
Abstract Number: 166

Validity and Sensitivity to Change of the Semi-Quantitative Omeract Ultrasound Scoring System for Tenosynovitis in Patients with Rheumatoid Arthritis
Abstract Number: 1191

Validity Evidence for Two Objective Structured Clinical Examination Stations to Assess Core Examination Skills of the Shoulder and Knee
Abstract Number: 672

Validity of Ankylosing Spondylitis Diagnoses in the Health Improvement Network
Abstract Number: 52

Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian As Patients
Abstract Number: 120

Validity of the Inpatient Diagnosis of Systemic Lupus Erythematosus: Clarifying Hospital Readmission Rates
Abstract Number: 1340

Value of 18F-FDG PET for Therapeutic Assessment in Patients with Polymyalgia Rheumatica Treated in First Line By Tocilizumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].